Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasm
Interventions: DRUG: doxorubicin, cyclophosphamide, paclitaxel, trastuzumab|DRUG: PLD, cyclophosphamide, trastuzumab, paclitaxel
Sponsor: Merck Sharp & Dohme LLC